Nektar Therapeutics (NKTR) Total Liabilities (2010 - 2026)

Nektar Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $187.1 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 22.86% year-over-year to $187.1 million; the TTM figure through Mar 2026 stood at $187.1 million (down 22.86% YoY), while the FY2025 annual figure was $190.6 million, down 21.61% from the prior year.
• Total Liabilities was $187.1 million for Q1 2026 at Nektar Therapeutics, down from $190.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $416.2 million in Q1 2022 to a low of $187.1 million in Q1 2026.
• Historically, Total Liabilities has averaged $282.6 million across 5 years, with a median of $267.0 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities retreated 26.27% in 2023, then retreated 8.41% in 2024.
• A 5-year view of Total Liabilities shows it stood at $344.0 million in 2022, then retreated by 22.36% to $267.0 million in 2023, then declined by 8.96% to $243.1 million in 2024, then decreased by 21.61% to $190.6 million in 2025, then decreased by 1.85% to $187.1 million in 2026.
• The last three Total Liabilities figures came in at $187.1 million (Q1 2026), $190.6 million (Q4 2025), and $216.3 million (Q3 2025), per Business Quant data.